Back to search

Peptide record

TPDB41503

FLAK93B Anticancer standard
12 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41503
FLAK93B
Anticancer
Cancer-related peptides
ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb iACP-DRLF pep-lab
standard
No
A 12-aa standard natural anticancer peptide sequence curated from ACP740 _ACP240, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KWKLAKKALALL-NH2
Physicochemical Analysis
C68H119N17O13
RNDCEQGHIMFPSTYV
LK
1382.80
11.00
4
0
8
+4
-0.64
0.342
155.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
397.74
0
Residue Composition
number
3
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
4
L
4
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 4 K: 4 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
12
C68H119N17O13
1382.80
11.00
+4
-0.64
0.342
Amidation
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 6 records
Evidence 1 Activity

Activity

LD50
LD50 =44 µg/ml
Anticancer
44 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50
LD50 =38 µg/ml
Anticancer
38 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =38 µg/ml
Anticancer
38 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =115 µg/ml
Anticancer
115 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =60 µg/ml
Anticancer
60 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =55 µg/ml
Anticancer
55 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2